Analyst Price Targets — ALNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 12:18 pm | — | Canaccord Genuity | $429.00 | $314.40 | TheFly | Alnylam price target raised to $429 from $415 at Canaccord |
| February 13, 2026 3:40 pm | — | Morgan Stanley | $360.00 | $313.75 | TheFly | Alnylam price target lowered to $360 from $408 at Morgan Stanley |
| February 13, 2026 2:23 pm | — | Bernstein | $451.00 | $312.43 | TheFly | Alnylam price target lowered to $451 from $491 at Bernstein |
| February 13, 2026 9:29 am | — | Chardan Capital | $425.00 | $308.48 | TheFly | Alnylam price target lowered to $425 from $475 at Chardan |
| February 12, 2026 6:14 pm | Paul Matteis | Stifel Nicolaus | $444.00 | $313.05 | TheFly | Alnylam price target lowered to $444 from $508 at Stifel |
| January 30, 2026 11:04 am | — | H.C. Wainwright | $510.00 | $346.79 | TheFly | Alnylam price target lowered to $510 from $570 at H.C. Wainwright |
| January 20, 2026 12:47 pm | — | RBC Capital | $465.00 | $359.00 | TheFly | Alnylam price target lowered to $465 from $500 at RBC Capital |
| January 20, 2026 11:04 am | — | Wells Fargo | $376.00 | $359.00 | TheFly | Alnylam price target lowered to $376 from $479 at Wells Fargo |
| January 12, 2026 12:41 pm | — | Needham | $529.00 | $398.29 | TheFly | Alnylam price target raised to $529 from $520 at Needham |
| January 12, 2026 9:48 am | Martin Auster | Raymond James | $472.00 | $398.29 | StreetInsider | Raymond James Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) |
Latest News for ALNY
Netflix outperformed during the period as investor concerns around a potential acquisition of Warner Bros. Discovery subsided. Microsoft lagged during the quarter despite reporting strong underlying results, as investor focus remained on slightly softer Azure growth and elevated AI-related investment. We believe Alnylam Pharmaceuticals' differentiated platform and growing pipeline position it well for sustained…
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2026 results as well as expectations for the future via…
Massachusetts Financial Services Co. MA lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 38.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 495,307 shares of the biopharmaceutical company's stock after acquiring an additional 138,778 shares during the quarter.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) insider Melissa Mclaughlin sold 1,624 shares of the business's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $319.59, for a total value of $519,014.16. Following the transaction, the insider directly owned 11,729 shares in the company,
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) insider Melissa Mclaughlin sold 2,286 shares of the company's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares of the company's stock,
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALNY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.